Oral agents and Outpatient Injections
FUNDING:
Cancer patients may receive treatment at cancer centres, their community hospitals, or taken at home. Alberta provides cancer drugs specified in the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents for the treatment of cancer.
FORMULARIES:
Alberta Health Drug Benefit List - Click Here
Alberta Health Services Outpatient Cancer Drug Benefit Program - Click Here
Drug (Brand Name) Manufacturer |
Indication | Strength, Route | DIN | Provincial Funding Eligibility Criteria | References | Patient Assistance Programs |
---|---|---|---|---|---|---|
Abiraterone (Zytiga) Janssen Inc. Generic | mCRPC | Oral |
Not specified |
Group 2* Eligibility:
*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. |
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
|
Abiraterone (Zytiga) Janssen Inc. Generic | mCSPC | Oral |
Not specified |
Group 2* Eligibility:
*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. |
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
|
Alendronate Generic | Osteoporosis | 70 mg PO |
Multiple |
Regular Benefit: No form required |
Apotex: Access Here |
|
Apalutamide (Erleada) Janssen Inc. | nmCRPC | Tablet, PO, 60mg, 240mg |
02478374 |
Group 2* Eligibility:
*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. **60 mg tablet funded, 240 mg tablet pending provincial funding decision. |
Janssen BioAdvance Patient Assistance Program: Access Here |
|
Apalutamide (Erleada) Janssen Inc. | mCSPC | Tablet, PO, 60mg, 240mg |
025478374 |
Group 2* Eligibility:
*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. **60 mg tablet funded, 240 mg tablet pending provincial funding decision. |
Janssen BioAdvance Patient Assistance Program: Access Here |
|
Darolutamide (Nubeqa) Bayer | nmCRPC | Oral |
Not specified |
Group 2* Eligibility:
*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. |
Bayer Patient Support Programs: Access Here Nubeqa Support Services: Access Here |
|
Denosumab (Prolia) Amgen | Osteoporosis | 60 mg / Syr Injection |
02343541 |
Special authorization Eligibility:
|
ProVital Program: Access Here |
|
Denosumab (Prolia) Amgen | mCRPC + Bone mets | 120 mg / Vial Injection |
02368153 |
Not a benefit |
The VICTORY Program: Access Here |
|
Enzalutamide (Xtandi) Astellas | mCRPC | Oral |
Not specified |
Group 2* Eligibility:
*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. |
Assistance Program: Access Here |
|
Enzalutamide (Xtandi) Astellas | mCSPC | Oral |
Not specified |
Group 2* Eligibility:
*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. |
Expedite® Patient Assistance Program: Access Here |
|
Enzalutamide (Xtandi) Astellas | nmCRPC | Oral |
Not specified |
Group 2* Eligibility:
*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. |
Expedite® Patient Assistance Program: Access Here |
|
Niraparib and abiraterone acetate (AKEEGA®) Janssen Inc. | nmCRPC | Dual-action tablet, PO/ Comprimé à double action, PO :100mg niraparib/500mg abiraterone acetate |
02538563 |
Pending provincial funding decision |
N/A |
Janssen BioAdvance Patient Assistance Program: Acess Here |
Olaparib (Lynparza) AstraZeneca | mCRPC | 100 mg tab | 150 mg tab |
100mg: 02475200 | 150mg: 02475219 |
Olaparib monotherapy for the treatment of metastatic castration resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline and / or somatic mutations in the homologous recombination repair (HRR) genes BRCA 1/2 or ATM who have progressed following prior treatment with an androgen receptor – axis targeted therapy (ARAT). Olaparib may be offered to patients who are unable to tolerate an ARAT. Patients who have received prior taxane based chemotherapy are eligible. |
AstraZeneca Patient Support Program: Access Here |